NASDAQ$REPL
Replimune Group Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Reported financial results for the fiscal fourth quarter and year ended March 31, 2020, and provided a business update.
Replimune Group, Inc. announced its financial results for the fiscal fourth quarter and year ended March 31, 2020. The company is focused on developing oncolytic immuno-gene therapies and plans to initiate clinical development of RP1 in anti-PD1 refractory patients with non-small cell lung cancer (NSCLC).
- Continued progress developing pipeline of oncolytic immuno-gene therapies.
- Released additional data with RP1 in lead indications of cutaneous squamous cell carcinoma (CSCC) and anti-PD1 refractory cutaneous melanoma.
- Announced plans to initiate clinical development of RP1 in anti-PD1 refractory patients with non-small cell lung cancer (NSCLC).
- Established clinical proof of principle with RP1 in immune-responsive tumor types.
Headline financials
Revenue & EPS history
Replimune · Revenue · Quarterly
$0
Forward guidance
Replimune believes that its existing cash and cash equivalents and short-term investments along with its debt commitments will enable it to fund its operating expenses and capital expenditure requirements through 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2020
+3.7%
Avg return
Earnings day
+2.3%
Avg return
5 days after
-1.0%
Avg return
30 days after
58%
18 / 31 earnings
Positive
+86.3%
Q4 2026
Best reaction
-11.8%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +86.3% | +114.2% | — | |
| Q3 2026 | +6.0% | +11.1% | +0.9% | |
| Q2 2026 | -0.8% | +6.4% | +23.7% | |
| Q1 2026 | -0.4% | -4.5% | +15.1% | |
| Q4 2025 | +3.9% | -0.5% | +9.6% | |
| Q3 2025 | +7.3% | +9.7% | -9.3% | |
| Q2 2025 | -6.5% | -13.6% | -2.2% | |
| Q1 2025 | +4.1% | +5.8% | +12.7% | |
| Q4 2024 | +1.5% | -11.5% | +24.7% | |
| Q3 2024 | +4.6% | -3.6% | +21.7% | |
| Q2 2024 | -10.3% | -13.7% | -40.9% | |
| Q1 2024 | -7.2% | -14.2% | -7.5% | |
| Q4 2023 | +0.4% | -0.2% | +22.3% | |
| Q3 2023 | -11.2% | -13.0% | -33.6% | |
| Q2 2023 | -3.5% | -6.1% | +5.8% | |
| Q1 2023 | +0.0% | -2.6% | -8.0% | |
| Q4 2022 | +3.9% | -0.6% | +6.8% | |
| Q3 2022 | -0.7% | +0.5% | -16.4% | |
| Q2 2022 | +0.9% | +0.2% | -16.6% | |
| Q1 2022 | -11.8% | -12.9% | -9.3% | |
| Q4 2021 | +5.7% | +5.8% | +3.3% | |
| Q3 2021 | +12.8% | +7.2% | -8.2% | |
| Q2 2021 | -1.6% | -6.2% | -1.1% | |
| Q1 2021 | +14.6% | +10.2% | +7.7% | |
| Q4 2020 | +17.8% | +19.5% | +11.0% | |
| Q3 2020 | -1.6% | -1.4% | -31.3% | |
| Q2 2020 | -1.3% | -27.9% | -12.5% | |
| Q1 2020 | -0.8% | +6.3% | +18.6% | |
| Q4 2019 | +1.4% | +1.4% | -5.7% | |
| Q3 2019 | +0.9% | -2.7% | -17.5% | |
| Q2 2019 | +0.7% | +8.9% | +7.2% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro